Compare · IKT vs RVMD
IKT vs RVMD
Side-by-side comparison of Inhibikase Therapeutics Inc. (IKT) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IKT and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $34.87B, about 188.3x IKT ($185.2M).
- RVMD has been more active in the news (16 items in the past 4 weeks vs 4 for IKT).
- RVMD has more recent analyst coverage (25 ratings vs 8 for IKT).
- Company
- Inhibikase Therapeutics Inc.
- Revolution Medicines Inc.
- Price
- -
- -
- Market cap
- $185.2M
- $34.87B
- 1M return
- -
- -14.11%
- 1Y return
- -
- +130.99%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2020
- News (4w)
- 4
- 16
- Recent ratings
- 8
- 25
Inhibikase Therapeutics Inc.
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It also develops IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body. The company has collaborations with The Johns Hopkins University; Louisiana State University School of Medicine, Shreveport; and Memorial Sloan-Kettering Cancer Center. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest IKT
- SEC Form 10-Q filed by Inhibikase Therapeutics Inc.
- Inhibikase Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Inhibikase Therapeutics Announces Third Quarter 2026 Financial Results and Highlights Recent Activity
- Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026
- SEC Form 4 filed by Inhibikase Therapeutics Inc.
- SEC Form 3 filed by Inhibikase Therapeutics Inc.
- SEC Form 8-K filed by Inhibikase Therapeutics Inc.
- Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors
- Chardan Capital Markets initiated coverage on Inhibikase Therapeutics with a new price target
- Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Latest RVMD
- Revolution Medicines Presents Updated Phase 1/2 Data for RASONQUE® (daraxonrasib) Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026
- Officer Stephen Michael Kelsey exercised 27,160 shares at a strike of $18.56 and sold $4,559,209 worth of shares (27,160 units at $167.86) as part of a pre-agreed trading plan (SEC Form 4)
- Director Flavia Borellini exercised 2,500 shares at a strike of $37.54, increasing direct ownership by 10% to 28,715 units (SEC Form 4)
- SEC Form 144 filed by Revolution Medicines Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.
- European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
- Director Borisy Alexis gifted 10,625 shares, decreasing direct ownership by 0.45% to 2,329,450 units (SEC Form 4)
- Chief Financial Officer Anders Jack exercised 35,750 shares at a strike of $29.19 and sold $6,724,688 worth of shares (35,750 units at $188.10) as part of a pre-agreed trading plan (SEC Form 4)
- Officer Mancini Anthony exercised 811 shares at a strike of $33.70 and sold $162,200 worth of shares (811 units at $200.00) as part of a pre-agreed trading plan (SEC Form 4)